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Background: The accentuated nitric oxide (NO) release that is induced by the systemic inflammatory response 
associated with infective endocarditis (IE) and cardiopulmonary bypass (CPB) may result in catecholamine refractory 
hypotension (vasoplegia) and increased transfusion requirement due to platelet inhibition. Methylene blue (MB) is 
an inhibitory drug of inducible NO. We aimed to evaluate the effect of prophylactic MB administration before CPB on 
vasopressor and transfusion requirements in patients with IE undergoing valvular heart surgery (VHS). 
Methods: Forty-two adult patients were randomly assigned to receive 2 mg/kg of MB (MB group, n = 21) or saline 
(control group, n = 21) for 20 min before the initiation of CPB. The primary end points were comparisons of 
vasopressor requirements serially assessed after weaning from CPB and hemodynamic parameters serially recorded 
before and after CPB. The secondary endpoint was the comparison of transfusion requirements.
Results: Two patients in the control group received MB after weaning from CPB due to norepinephrine and 
vasopressin refractory vasoplegia and were thus excluded. There were no significant differences in vasopressor 
requirements and hemodynamic parameters between the two groups. The mean number of units of packed 
erythrocytes transfused per transfused patient was significantly less in the MB group. The numbers of patients 
transfused with fresh frozen plasma and platelet concentrates were less in the MB group.
Conclusions: In IE patients undergoing VHS, prophylactic MB administration before CPB did not confer significant 
benefits in terms of vasopressor requirements and hemodynamic parameters, but it was associated with a significant 
reduction in transfusion requirement. (Korean J Anesthesiol 2012; 63: 142-148)
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Introduction
Infective endocarditis (IE) is a life-threatening disease that 
is associated with severe valvular dysfunction which occasio-
nally requires surgical correction as a definite treatment 
[1,2]. IE produces a broad spectrum of systemic signs and 
symptoms related to systemic inflammatory response and 
endothelial nitric oxide (NO) release [2]. NO is associated 
with arterial vasodilatation and high cardiac output, and 
with decreased sensitivity of the heart and peripheral vessels 
to sympathomimetic agents [1]. In addition, NO is a potent 
inhibitor of platelet adhesion and aggregation [3]. More-
over, the process of valvular heart surgery (VHS) with cardio-
pulmonary bypass (CPB) may exacerbate pre-existing 
systemic inflammatory response [4], which will result in a 
profound reduction in systemic vascular resistance (SVR) and 
vasodilatory shock. This is an important issue in perioperative 
anesthetic management [5,6]. 
Thus, patients with IE who are undergoing cardiac surgery 
are potentially at increased risk of refractory hypotension 
related to vasoplegia and bleeding complications. 
Methylene blue (MB) has been used as an inhibitory drug 
of NO to treat refractory hypotension in anaphylaxis, septic 
shock and after CPB [6-8]. MB prevents elevation of the level 
of cyclic guanosine 3’5’-monophosphate (cGMP) by inhibiting 
guanylate cyclase, thereby blocking the cGMP-dependent 
vasodilatory effects of NO [9]. In patients with septic shock, 
MB effectively increased arterial blood pressure, SVR, and 
left ventricular stroke work without significant impact on 
cardiac output, oxygen delivery, and/or oxygen consumption 
[10]. Furthermore, the proper use of MB for the treatment of 
vasoplegic shock could reduce mortality and morbidity in 
patients undergoing cardiac surgery [6,7,11]. Regarding IE, 
there have been case reports of successful management of 
the refractory hypotension caused by IE with MB [1,12], but a 
prospective study of the use of MB in IE patients undergoing 
VHS has not yet been conducted. 
In this prospective double blinded and randomized trial, we 
aimed to evaluate the effect of prophylactic MB administration 
before CPB on the use of vasopressors and hemodynamic 
parameters in patients with IE undergoing VHS. Additionally, 
transfusion requirements were also compared, considering the 
effect of MB on platelet function.
Materials and Methods
After IRB approval and receiving patients’ consent, forty 
two patients with IE scheduled for VHS were included in this 
prospective, randomized study. All patients were treated with 
antibiotics for more than four weeks and were scheduled for 
surgery electively. Patients with positive blood cultures or signs 
of active inflammation including fever (> 38oC) or leukocytosis 
(white blood cell count > 11 × 103/μl) were excluded [13]. 
In addition, patients with ASA classification > 4, preexisting 
lung parenchymal disease, severe hepatic or renal disease, 
cerebrovascular disease or coronary artery disease requiring 
surgical revascularization were also excluded. After induction, 
patients were randomly assigned to either the control group (n = 
21) or the MB group (n = 21) using a computerized randomized 
table. In the MB group, 2 mg/kg of MB was infused for 20 min 
before the start of CPB. In the control group, an equivalent 
volume of normal saline was infused instead of MB. To ensure 
blinding, the drugs were prepared by an anesthesiology 
nurse who was not involved in the study. Since the MB has a 
blue color, syringes were wrapped in aluminum foil. Cardiac 
surgeons and attending anesthesiologists were also blinded to 
the assigned group until the end of statistical analysis. 
All cardiac medications except diuretics were continued until 
the day of surgery. Radial and pulmonary artery catheters were 
inserted under local anesthesia before anesthetic induction. 
Anesthesia was induced with intravenous midazolam (0.03-0.07 
mg/kg), sufentanil (1.5-3.0 μg/kg) and rocuronium (0.9 mg/
kg). After tracheal intubation, patients’ lungs were mechanically 
ventilated with 40% oxygen with air to maintain normocarbia 
(PaCO2 35 ± 5 mmHg). Anesthesia was maintained with 
sufentanil (0.5-1.5 μg/kg/h), sevoflurane or isoflurane and 
vecuronium (1-2 μg/kg/min). Persistent hypotension was 
treated with norepinephrine infusion before CPB. 
All patients received standard surgical and CPB manage-
ment. CPB was instituted with a membrane oxygenator. Body 
temperature was maintained under mild hypothermia (32-
33oC) and the α-stat was used for acid-base management. 
Pump flow was maintained at a rate of 2.0-2.5 L/min/m2 using 
non-pulsatile flow, and a blood cardioplegic solution was used. 
During the perioperative period including CPB, mean arterial 
blood pressure (MBP) was maintained at 55-80 mmHg using 
norepinephrine or vasopressin. Norepinephrine was chosen as 
the primary vasopressor for treating systemic hypotension and 
vasopressin was added when the norepinephrine requirement 
exceeded 0.3 μg/kg/min. Milrinone was used if the left ventri-
cular ejection fraction was lower than 30% (as measured by 
transesophageal echocardiography) after CPB, in case of right 
ventricular dysfunction or pulmonary hypertension (a mean 
pulmonary arterial pressure [MPAP] greater than 50 mmHg). 
The criteria for transfusion of packed red blood cells (pRBC) 
were a hematocrit level below 21% during CPB and below 25% 
during the remaining perioperative period. Fresh frozen plasma 
(FFP) was transfused when the international normalized ratio 
was greater than 1.5 with excessive bleeding greater than 200 
ml/h for two consecutive hours in the postoperative period. 
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Platelet concentrates (PLT) were transfused when the platelet 
count was less than 50,000/mm3 with excessive bleeding above 
200 ml/h for two consecutive hours in the postoperative period.
Hemodynamic variables were recorded, including MBP, 
heart rate (HR), MPAP, central venous pressure (CVP), pulmo-
nary capillary wedge pressure (PCWP), cardiac index (CI) and 
SVR (80 × [MBP - CVP]/cardiac output). Measurements were 
performed before CPB (baseline), 20 minutes after weaning 
from CPB (T2), at sternum closure (T3), and immediately after 
(T4) and 12 hours after intensive care unit (ICU) arrival (T5). 
Vasopressor and milrinone requirements were assessed at the 
same time points excluding that before CPB, when none of the 
patients required any vasopressor or milrinone. Thus, their 
requirements were assessed immediately after weaning from 
CPB (T1) and at T2, T3, T4 and T5. 
All patients were transferred to ICU after surgery, and 
received standard management according to institutional 
guide lines by the ICU staff consisting of anesthesiologists and 
a cardiac surgeon not involved in this study. Postoperative 
fluid management was performed to keep PCWP between 
10 and 14 mmHg, CI > 2 L/min/m2, and urinary output > 
0.5 ml/kg/h. The length of stay in ICU and the duration of 
postoperative hospitalization were recorded. In addition, major 
morbidity endpoints including renal failure (new increase of 
serum creatinine > 2.0 mg/dl or > 50% over baseline or a new 
requirement for dialysis), cerebrovascular event, deep sternal 
wound infection, ventilator care > 48 h and/or hemostatic 
reoperation were recorded by anesthesiologists not aware 
of this study [14]. Hemostatic reoperation was indicated 
when chest tube drainage was greater than 200 ml/h for six 
consecutive hours or greater than 400 ml during the first 
hour despite a normalized activated clotting time and global 
coagulation status. Decisions for extubation and discharge from 
the ICU were also made according to institutional guidelines at 
the discretion of the ICU staff, as described elsewhere [15].
Statistical analysis
All statistical analyses were performed using SPSS (SPSSFW, 
SPSS Inc., Chicago, IL, USA). The primary end point of this 
study was to evaluate the amount of infused norepinephrine 
during and after CPB. A difference of 0.1 μg/kg/min in the 
norepinephrine infusion rate between the groups was taken 
as clinically significant. Based on the institutional results for 
IE patients who underwent VHS, the standard deviation of 
norepinephrine infusion was 0.1 μg/kg/min. This calculation 
generated an estimated 18 patients in each group with 80% 
power and an alpha level of 0.05. Considering the 10% of drop-
out rate, 20 patients in each group were enrolled. All data were 
expressed as the number of patients or the mean ± SD. The 
normality of distribution was assessed using a q-q plot and 
the Shapiro-Wilk test. Between-group data was compared by 
the χ2 test, Fisher’s exact test, independent t-test with post hoc 
comparison using the Bonferroni test or Mann-Whitney U test 
with same post hoc comparison as appropriate. Continuous 
variables were presented as mean ± SD or median [interquartile 
range], and dichotomous variables were presented as number. 
A P value < 0.05 was considered as significant.
Results
Two patients demonstrated refractory hypotension despite 
norepinephrine and vasopressin infusion. They were revealed 
as patients in the control group and MB was infused after CPB. 
After MB administration, their blood pressure was successfully 
restored to the predefined target range. The data of these two 
patients were excluded from statistical analysis.
Patient characteristics were similar between the two 
groups, apart from the fact that the number of patients with 
hypertension was significantly higher in the control group than 
in the MB group. The type of valvular surgery performed, and 
the duration of CPB and aortic cross clamp were not statistically 
different between groups (Table 1). 
Table 1. Patient Characteristics
Control 
(n = 19)
MB 
(n = 21)
P value
Age (yr)
Sex (M/F)
Height (cm)
Weight (kg)
Diabetes mellitus (n)
Hypertension (n)
Pre-operative LVEF (%)
Pre-operative medications  
    β-blockers (n) 
    Calcium channel blockers (n) 
    Renin angiotensin inhibitors (n) 
    Nitrate (n)
    Sigmart (n)
    Digoxin (n)
    Diuretics (n) 
Operation
    Mitral valve replacement (n)
    Aortic valve replacement (n)
    Tricuspid annuloplasty (n)
    Coronary artery bypass graft (n)
Duration of ACC (min)
Duration of CPB (min)
47.6 ± 20.7
14/5
168.2 ± 8.8
56.9 ± 14.3
2
8
68.5 ± 8.2
3
4
8
0
0
2
11
14
9
2
2
76.5 ± 25.9
102.5 ± 26.6
42.8 ± 11.4
12/9
167.2 ± 7.6
59.6 ± 10.8
3
  1*
66.9 ± 11.2
3
4
10
1
1
4
15
18
7
1
1
76.0 ± 26.9
106.0 ± 30.5
0.362
0.273
0.698
0.501
0.720
0.005
0.607
0.894
0.874
0.726
0.335
0.335
0.451
0.370
0.342
0.366
0.489
0.489
0.960
0.697
Values are number or mean ± standard deviation. LVEF: left ventri-
cular ejection fraction, ACC: aortic cross clamp, CPB: cardio pul-
monary bypass, MB: patients received 2 mg/kg of methylene blue 
was infused for 20 min before the start of CPB, Control: patients 
received equivalent amount of normal saline was infused at the same 
time. *P < 0.05 compared to the control group.
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The hemodynamic variables, including MBP, HR, MPAP, 
CVP, PCWP, CI and SVR, were similar in both groups throughout 
the study period (Table 2).
The required amount of vasopressor and the number of 
patients requiring vasopressors or an inotropic agent during 
weaning from CPB and the postoperative period were not 
statistically different between the groups (Table 3). 
Until 24 hours after the operation, the mean number of units 
of pRBC trasnfused per transfused patient was significantly less 
in the MB group, although the number of patients transfused 
Table 2. Changes in Hemodynamic Variables
Baseline T2 T3 T4 T5
MBP (mmHg)
    Control
    MB
Heart rate (beats/min)
    Control
    MB
CVP (mmHg)
    Control
    MB
MPAP (mmHg)
    Control
    MB
PCWP (mmHg)
    Control
    MB
CI (L/m2/min) 
    Control
    MB
SVR (dynes·sec/cm5)
    Control
    MB
68.2 ± 12.5
72.4 ± 10.1
78.4 ± 14.1
83.1 ± 19.2
8.5 ± 3.8
9.3 ± 4.7
24.9 ± 10.2
30.4 ± 13.3
18.3 ± 7.7
22.5 ± 11.2
2.7 ± 0.6
2.8 ± 0.9
1,175 ± 318
1,185 ± 376
67.8 ± 11.2
61.7 ± 10.8
91.2 ± 12.9
89.0 ± 13.0
8.5 ± 2.3
9.3 ± 1.7
18.9 ± 4.1
20.3 ± 4.4
13.7 ± 3.7
14.7 ± 4.0
3.4 ± 0.6
3.4 ± 0.6
916 ± 268
843 ± 326
68.3 ± 7.6
64.3 ± 6.4
95.2 ± 12.5
93.2 ± 15.2
9.8 ± 3.2
10.5 ± 1.8
19.1 ± 5.7
20.9 ± 4.7
14.7 ± 3.4
15.3 ± 4.4
3.4 ± 0.7
3.5 ± 0.9
948 ± 249
870 ± 343
77.6 ± 13.7
78.6 ± 12.7
93.8 ± 11.5
94.1 ± 15.6
7.7 ± 3.0
9.1 ± 2.9
18.1 ± 3.5
20.3 ± 6.4
12.9 ± 2.7
15.0 ± 5.1
3.8 ± 1.3
3.5 ± 1.0
960 ± 304
1,085 ± 540
74.5 ± 8.1
76.1 ± 12.3
85.6 ± 12.4
85.2 ± 12.8
8.9 ± 2.1
8.5 ± 2.2
17.4 ± 2.5
18.0 ± 5.4
12.7 ± 2.1
13.5 ± 4.8
3.3 ± 0.7
2.9 ± 0.6
1,071 ± 286
1,138 ± 330
Values represent mean ± standard deviation. Baseline: pre-cardiopulmonary bypass, T2: 20 min after weaning from cardiopulmonary bypass, 
T3: sternum closure, T4: at intensive care unit arrival, T5: 12 hr after weaning from cardiopulmonary bypass, MBP: mean blood pressure, 
CVP: central venous pressure, MPAP: mean pulmonary arterial pressure, PCWP: pulmonary capillary wedge pressure, CI: cardiac index, SVR: 
systemic vascular resistance. MB: patients received 2 mg/kg of methylene blue, infused for 20 min before the start of cardiopulmonary bypass, 
Control: patients received an equivalent amount of normal saline, infused at the same time. All P values of intergroup comparisons were above 
0.05.
Table 3. Perioperative Vasopressor and Milrinone Requirement
T1 T2 T3 T4 T5
Norepinephrine 
    Control (µg/kg/min)
    MB (µg/kg/min)
    Control (n)
    MB (n)
Vasopressin
    Control (u/h)
    MB (u/h)
    Control (n)
    MB (n)
Milrinone
    Control (µg/kg/min) 
    MB (µg/kg/min)
    Control (n)
    MB (n)
0.09 (0.05-0.17)
0.06 (0.01-0.14)
14
13
0 (0-4)
0 (0-3)
7
4
  0 (0-0.41)
0 (0-0.5)
5
6
0.06 (0-0.17)
0.05 (0-0.16)
14
18
0 (0-0)
0 (0-0)
5
7
0 (0-0)
0 (0-0)
5
9
0.07 (0-0.20)
      0 (0-0.09)
14
15
   0 (0-1.8)
0 (0-4)
7
12
0 (0-0)
0 (0-0)
5
9
0.02 (0-0.05)
0.02 (0-0.04)
12
15
0 (0-2)
    0 (0-2.8)
7
7
0 (0-0.41)
0 (0-0.31)
6
8
0 (0-0.01)
0 (0-0.01)
10
10
0 (0-0)
0 (0-0)
1
2
0 (0-0.39)
0 (0-0.47)
8
9
Values are the number or median (interquartile range). T1: immediately after weaning from cardiopulmonary bypass, T2: 20 min after weaning 
from cardiopulmonary bypass, T3: sternum closure, T4: at intensive care unit arrival, T5: 12 hr after weaning from cardiopulmonary bypass. 
MB: patients received 2 mg/kg of methylene blue,infused for 20 min before the start of cardiopulmonary bypass, Control: patients received an 
equivalent amount of normal saline infused at the same time. All P values of intergroup comparisons were above 0.05.
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with pRBC was not different between the groups. The number 
of patients transfused with FFP (P = 0.049) and PLT (P = 0.057) 
was smaller in the MB group while the mean number of units 
of transfused FFP and PLT per transfused patient were not 
different. The incidences of assessed major morbidity endpoints 
were all similar between the groups. The durations of ICU and 
hospital stays were also similar between the groups (Table 4).
Discussion
In this prospective, randomized and controlled trial, pro-
phylactic MB administration before CPB did not provide 
significant benefit in terms of vasopressor requirement in 
IE patients undergoing VHS, while MB partially conferred a 
beneficial effect on perioperative transfusion requirement. 
The incidence of IE is approximately 1.7-6.2 cases per 
100,000 patients [16]. While dental surgery was the main 
cause of IE in the past, it is now more likely related to previous 
VHS, degenerative valve disease, and nosocomial infection 
[17]. Most of the morbidities and mortality associated with 
IE are related to valvular dysfunction and abscess formation 
secondary to tissue destruction, heart failure and embolic 
events. VHS is required in approximately 50% of IE patients and 
can be a definite treatment, while the timing of operation plays 
an important role in patient outcomes [2]. In a patient with a 
stable medical condition, the operation can be delayed after 
antibiotic treatment in order to reduce the risk of preoperative 
complications and early prosthetic valve endocarditis. However, 
emergent operation should be considered if hemodynamic 
compromise, persistent infection despite appropriate antibiotic 
treatment, or large vegetations with high embolic potential are 
suspected [2]. 
In IE, bacterial endotoxin stimulates different types of 
cells to release cytokines and inflammatory mediators that 
activate the inducible nitric oxide synthase (iNOS), which 
increases the production of NO. NO in turn stimulates the 
production of cGMP. Excessive formation of NO and cGMP is 
related to profound vasodilatation, myocardial depression, and 
decreased response to catecholamines. Thus IE is associated 
with a systemic inflammatory response and frequent low SVR 
syndrome (vasoplegic syndrome, VS) [1], which is clinically 
expressed as severe hypotension or shock without response 
to volume expansion and which requires large amounts of 
vasopressor to maintain normotension. Furthermore, CPB 
during VHS may exacerbate the systemic inflammatory 
response, thereby predisposing the patients with IE to VS [6]. 
The important roles of NO in systemic inflammatory response 
and VS in IE patients undergoing VHS encourage the prophylactic 
use of NO-inhibitory drugs such as MB. For several decades, MB 
has been used to treat VS through inhibiting the vasodilatory 
effect of NO and other nitrovasodilators on the endothelium 
and vascular smooth muscle [7,18]. In a clinical study recruiting 
638 patients undergoing elective cardiac surgery, MB (1.5 mg/
kg) administered in patients with VS after CPB significantly 
lowered morbidity (0% vs. 21.4%) and resulted in a shorter 
postoperative recovery time [7], however, patients with IE 
were excluded from this study. Regarding septic endocarditis, 
there was a case report that administration of MB during 
CPB reversed refractory hypotension by increasing SVR and 
reducing vasopressor requirement in an adult patient [1]. In 
Table 4. In-hospital Postoperative Outcomes
Control (n = 19) MB (n = 21) P value
Postoperative 24 hr  blood loss (ml)
Postoperative 24 hr transfusion
    pRBC transfused patients (n)
    pRBC units/transfused patients
    FFP transfused patients (n)
    FFP units/transfused patients
    PLT transfused patients (n)
    PLT units/transfused patients
Major morbidity endpoints
    Renal failure (n)
    Ventilator care > 48 h (n)
    Cerebrovascular event (n)
    Deep sternal wound infection (n)
    Hemostatic reoperation (n)
Duration of ICU stay (d)
Duration of hospital stay (d)
502.9 ± 514.7
7
4.6 ± 2.9
8
4.6 ± 4.0
5
6.2 ± 4.1
9
2
2
1
1
1
4.7 ± 4.9
21.8 ± 8.8
483.8 ± 345.7
7
  1.6 ± 0.5*
  3*
2.0 ± 1.0
1
8
6
2
2
0
0
0
3.8 ± 2.0
18.4 ± 7.6
0.890
0.816
0.019
0.049
0.308
0.057
0.712
0.220
0.916
0.916
0.287
0.287
0.287
0.433
0.199
Values are number or mean ± standard deviation. pRBC: packed red blood cell, FFP: fresh frozen plasma, PLT: platelet concentrate, ICU: 
intensive care unit. MB: patients received 2 mg/kg of methylene blue, infused for 20 min before the start of cardiopulmonary bypass, Control: 
patients received an equivalent amount of normal saline, infused at the same time. *P < 0.05 compared to the control group. 
147www.ekja.org
Korean J Anesthesiol Cho, et al.
that case, a bolus of MB (2 mg/kg) before CPB was followed by 
continuous infusion (0.5-1 mg/kg/h) during and 30 min after 
CPB. On the contrary, in a case of pediatric patient with mitral 
valve endocarditis demonstrating refractory hypotension, MB 
was less effective than expected despite the use of same dosing 
regimen and protocol, and other vasopressor supports were 
required [12]. The influence of prophylactically administered 
MB before CPB on the occurrence of VS and the vasopressor 
requirement in patients with IE has not previously been addressed. 
Despite the above mentioned theoretical background, 
however, we could not observe any beneficial effects of 
prophylactic MB in terms of the amount of vasopressor require-
ment and hemodynamic parameters including SVR in the 
current study. There is currently no standardized MB admini-
stration protocol for the prevention or reversal of VS. MB has 
been administered preoperatively, before CPB, during CPB, and 
postoperatively [1,7,12,18,19]. Dosing for the treatment of VS 
has been reported to be variable, from 1.5 to 3 mg/kg up to as 
much as 7 mg/kg, and has been administered as an intravenous 
bolus with or without continuous infusion [7,12,20,21], while a 
loading of 2 mg/kg of MB for 20 min has been most commonly 
used. MB is not free of side effects: the most commonly 
reported adverse effects include cardiac arrhythmia, angina, 
decreased cardiac output, renal blood flow, resistance and a 
deterioration in gas exchange. These effects have been reported 
to usually occur at a dose of more than 2 mg/kg of MB. In 
addition, hemolytic anemia and hyperbilirubinemia has been 
reported with MB administration in doses in excess of 2 mg/kg, 
although occurrence has been rare [22,23]. Thus, we decided 
to administer a bolus of 2 mg/kg of MB without continuous 
infusion in this study. However, as the plasma concentration 
of MB sharply declines during the first 40 min after a bolus 
[24], continuous infusion in the next hours could have been 
helpful to maintain the therapeutic concentration during 
the perioperative period and may have conveyed different 
results. In pediatric patients, however, MB failed to improve 
hemodynamic profiles despite being administered as a bolus (2 
mg/kg) before CPB and then continuously infused (0.5-1 mg/
kg/h) during and after CPB [12].
Other possible reasons for the absence of beneficial effect 
of MB in the current study are as follows. Firstly, preoperative 
uses of angiotensin converting enzyme (ACE) inhibitors, 
calcium channel blockers (CCB) and heparin are known risk 
factors of VS in cardiac surgical patients. In the current study, 
most patients were treated with ACE inhibitors, CCB and 
heparin preoperatively in addition to IE itself. The concomitant 
use of these medications may have resulted in marked 
vasodilation, which may have been so overwhelming as to 
mask the preventive effect of a MB bolus. Secondly, it has been 
reported that a window of opportunity for MB efficacy exists 
in terms of helping to restore SVR, depending on the activity 
of soluble guanylate cyclase [21]. In a septic model, coincident 
with increased iNO expression, guanylate cyclase expression 
was exhausted due to excessive NO production and lack of 
counteraction of MB was observed [21]. Therefore, there is a 
possibility that guanylate cyclase may have been exhausted due 
to excessive activation of inflammatory system in IE patients, 
and thus MB could not confer beneficial influence. In the 
current study, two patients in the control group received MB 
after CPB because of excessive vasopressor requirement and 
interestingly, MB infusion successfully reversed refractory 
hypotension in these patients. This may be attributable to the 
fact that these patients were in the window of opportunity 
during which guanylate cylases were resynthesized, and MB 
could be effective again. As major hemodynamic variables such 
as CI, MBP and filling pressures were intended to be maintained 
within the predefined target range, the lack of difference in 
hemodynamic parameters including SVR is not surprising. 
Yet, the lack of difference in vasopressor requirements in 
order to achieve a certain hemodynamic goal precludes any 
conclusive benefit of prophylactic MB administration in terms of 
hemodynamic management. Therefore, more studies addressing 
the optimal timing and regimen of MB for the treatment of VS in 
IE patients undergoing VHS seem to be required.
NO was reported to be involved in the pathogenesis of the 
bleeding tendency as a potent inhibitor of platelet adhesion and 
aggregation [3]. In one animal study, N-monimethyl-Larginine, 
an inhibitor of NO formation from L-arginine, completely 
normalized the bleeding time in rats with renal mass reduction 
and uremia with bleeding tendency [25]. Systemic inhibition of 
NO production also shortened bleeding time in humans [26]. In 
the current study, there was a distinct trend toward significantly 
fewer patients requiring FFP and PLT transfusion during 
postoperative 24 hours in the MB group. Furthermore, although 
the number of patients transfused with pRBC was similar, the 
amount of pRBC transfused per patient was significantly less. 
These results are in agreement with the result of a previous study 
that demonstrated a reduction in the amount of transfusion in 
an MB group in coronary artery bypass graft surgery patients 
[19]. Similar postoperative blood loss between groups might 
be associated with the fact that the frequent use of FFP and 
PLT in the control group may have resulted in reduced late 
postoperative bleeding.
The limitation of this study is as follows. Inclusion of patients 
in the acute phase of IE would have revealed more definite 
results. However, cardiac surgery for IE is usually performed 
after stabilization with antibiotics treatment for as long as the 
patient’s clinical condition permits. Accordingly, it would be 
challenging to enroll such patients in a sufficient number. 
Moreover, a study comparing stabilized IE patients with patients 
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without IE undergoing the same VHS revealed that patients with 
IE had a significantly higher incidence of heparin resistance and 
a higher postoperative stroke rate. These patients also required 
significantly longer postoperative hospitalization, implying an 
adverse prognosis despite stabilization [13]. 
In conclusion, the preventive use of MB before CPB did 
not result in significant beneficial effects in terms of reducing 
perioperative vasopressor requirement and improving hemo-
dynamic variables, but there were significant reductions in the 
incidence of FFP and PLT transfusion and a lower amount of 
pRBC transfusion per patient seen in the MB group. Considering 
its proven beneficial clinical effects, further evaluation of the 
proper administration protocol, including treatment timing and 
continuous infusion, seems to be warranted. 
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